Clinical Trials

A Phase 1/2a Study of STM-416 Administered Intraoperatively to Patients Undergoing Transurethral Resection of Bladder Tumor (TURBT) for Recurrent High-Grade Papillary Bladder Cancer

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Principal Investigator

Ahmed Mansour Elkenany MD

For more information about this study
View Details

About This Study

This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.